{
    "clinical_study": {
        "@rank": "139369", 
        "acronym": "IMMUNE", 
        "arm_group": [
            {
                "arm_group_label": "High-Dose Influenza Vaccine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Standard Trivalent Influenza Vaccine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The safety and immunogenicity of high dose influenza vaccine has not been studied in young\n      patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and\n      safety of high dose influenza to standard dose influenza vaccine in adult oncology patients\n      who are younger than 65 years old receiving chemotherapy."
        }, 
        "brief_title": "Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Influenza Viral Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Influenza, Human", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18 years old to less than 65 years old\n\n          2. Subjects with malignancy must be receiving chemotherapy\n\n          3. Medically stable\n\n          4. Able to understand and willingness to sign a written informed consent\n\n          5. Able to comply with study procedures\n\n          6. Life expectancy of more than 3 months\n\n          7. Adequate organ function:\n\n               -  ANC >1000/mm3\n\n               -  Platelet >100,000/uL\n\n               -  Creatinine <2 mg/dL\n\n               -  AST and ALT <3 times the ULN\n\n        Exclusion Criteria:\n\n          1. Allergy to eggs\n\n          2. Prior allergy to Influenza Vaccine\n\n          3. History of Guillain-Barre Syndrome\n\n          4. Current febrile illness\n\n          5. Other immunosuppressive disease (recipients of solid organ transplant, uncontrolled\n             HIV)\n\n          6. Autologous or Allogenic Stem Cell Transplant with in a year\n\n          7. Current immunotherapy or immunochemotherapy in the last 6 months (rituximab or\n             ofatumumab)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666782", 
            "org_study_id": "CIC 1336-B12-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Trivalent Influenza Vaccine", 
                "description": "Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.", 
                "intervention_name": "Standard Trivalent Influenza Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone"
            }, 
            {
                "arm_group_label": "High-Dose Influenza Vaccine", 
                "description": "Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.", 
                "intervention_name": "High-Dose Influenza Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Fluzone High-Dose"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Influenza vaccine", 
            "Oncology", 
            "Chemotherapy"
        ], 
        "lastchanged_date": "August 27, 2013", 
        "location": [
            {
                "contact": {
                    "email": "saad.jamshed@rochestergeneral.org", 
                    "last_name": "Saad Jamshed, MD", 
                    "phone": "585-922-4020"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14621"
                    }, 
                    "name": "Rochester General Hospital"
                }, 
                "investigator": {
                    "last_name": "Saad Jamshed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "saad.jamshed@rochestergeneral.org", 
                    "last_name": "Saad Jamshed, MD", 
                    "phone": "585-922-4020"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14625"
                    }, 
                    "name": "Lipson Cancer Center Linden Oaks Medical Campus"
                }, 
                "investigator": {
                    "last_name": "Saad Jamshed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy", 
        "overall_contact": {
            "email": "saad.jamshed@rochestergeneral.org", 
            "last_name": "Saad Jamshed, MD", 
            "phone": "585-922-4020"
        }, 
        "overall_official": {
            "affiliation": "Rochester General Hospital", 
            "last_name": "Saad Jamshed, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure Geometric Mean Titer (GMT) before and after vaccination at day 28.", 
            "measure": "The Geometric Mean Titer (GMT) of high-dose influenza vaccine vs the standard trivalent influenza vaccine in adult subjects on chemotherapy who are less than 65 years old.", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666782"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rochester General Hospital", 
            "investigator_full_name": "Saad Jamshed MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The seroprotection rate of high-dose influenza vaccine vs standard trivalent influenza vaccine in adult subjects on chemotherapy less than 65 years old.", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "The seroconversion rate of high-dose influenza vaccine versus standard trivalent influenza vaccine in adult subjects on chemotherapy less than 65 years old.", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Evaluate and compare the local and systemic adverse events to both vaccines.", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Rochester General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Saad Jamshed MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}